Which medications in the drug class Keratolytic Agents are used in the treatment of Basal Cell Carcinoma?

Updated: Mar 23, 2021
  • Author: Robert S Bader, MD; Chief Editor: William D James, MD  more...
  • Print

Keratolytic Agents

These agents decrease cohesiveness of abnormal hyperproliferative keratinocytes and may reduce potential for malignant degeneration. It modulates keratinocyte differentiation.

Tazarotene (Avage, Fabior, Tazorac)

Tazarotene is a retinoid prodrug with an active metabolite that modulates differentiation and proliferation of epithelial tissue; it also may have anti-inflammatory and immunomodulatory properties. It is not approved by the US Food and Drug Administration for treating basal cell carcinoma.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!